Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2009

View Archived Issues

Novel Flt3 inhibitors in early development at Biovitrum for proliferative disorders

Arpida and Evolva plan merger

Genfit progresses AD-Inov program in Alzheimer's disease

CytRx receives FDA letter regarding phase IIb arimoclomol trial in ALS

Affymax provides update for phase III Hematide program in chronic renal failure

Inviragen receives grant to support dengue vaccine development

QuatRx reports results of second pivotal phase III study of Ophena

NuPathe reports data from pivotal phase III Zelrix trial in acute migraine

Theravance and Astellas obtain FDA approval of Vibativ

Centocor Ortho Biotech receives two FDA Complete Response letters for Doxil combinations

Enrollment completed in phase III VEGF Trap-Eye studies in wet AMD

Cellerix's Cx-601 obtains EMEA orphan medicinal product status

StemCells to initiate neural stem cell trial in myelination disorder

GenSpera receives FDA approval to commence phase I G-202 trial in cancer

Atomoxetine improves symptoms of Parkinson's disease

LegoChem Biosciences describes novel cyclic amidrazone antibiotics

Details of phase II study with OP-145 in otitis media presented

Novel aminoglycoside ACHN-490 shows potent preclinical activity and clinical safety

Fatty acid synthase inhibitor UCM-Gi028 developed for anti-HER resistant cancer therapy

Long-term effects, cardiac safety and cognitive improvement assessed with fampridine-SR

Cephalon and Pharmacopeia describe histamine H3 receptor antagonists under development

New antibacterial compounds discovered by scientists at Princeton University

NovaBay and Galderma commence study of NVC-422 for impetigo

PTC Therapeutics initiates registration-directed phase III trial of ataluren in cystic fibrosis

Celldex Therapeutics doses first patient in phase I/II cancer vaccine trial

Verona reports final results of phase I/IIa RPL-554 trial in asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026